急性早幼粒细胞白血病的治疗演变
| 作者: |
1王丽娟,
1付玉,
1谭业辉
1 吉林大学第一医院血液科，长春 130021 |
| 通讯: |
谭业辉
Email: 276769165@qq.com |
| DOI: | 10.3978/j.issn.2095-6959.2019.05.028 |
| 基金: | 吉林省科技发展计划项目 (20170623092-TC-N012)。 |
摘要
急性早幼粒细胞白血病(acute promyelocy tic leukemia，APL)是急性髓系白血病的一种特殊亚型，早期病死率较高。APL治疗经历了蒽环类药物为主的联合化疗、全反式维甲酸(all-trans retinotic acid，ATRA)、三氧化二砷(arsenic trioxide，ATO)等阶段，随着其治疗方案的优化，该病已成为可以治愈的疾病之一。
关键词：
急性早幼粒细胞白血病；治疗；演变
Therapeutic evolution of acute promyelocytic leukemia
CorrespondingAuthor: TAN Yehui Email: 276769165@qq.com
DOI: 10.3978/j.issn.2095-6959.2019.05.028
Foundation: This work was supported by the Science and Technology Development Plan Project of Jilin Province, China (20170623092-TC-N012).
Abstract
Acute promyelocytic leukemia (APL) is a special subtype of acute myeloid leukemia with high early mortality.
APL treatment has undergone anthracycline-based combination chemotherapy, all-trans retinoic acid, and arsenic trioxide. With the optimization of its treatment plan, the disease has become one of the curable diseases.
Keywords：
acute promyelocytic leukemia; treatment; evolution
APL treatment has undergone anthracycline-based combination chemotherapy, all-trans retinoic acid, and arsenic trioxide. With the optimization of its treatment plan, the disease has become one of the curable diseases.